Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Relapsed/Refractory KMT2A-r Acute LeukemiaRelapsed/Refractory NUP98-r Acute LeukemiaRelapsed/Refractory NPM1-m Acute Leukemia
Interventions
DRUG

Ziftomenib

Oral capsule

DRUG

Cytarabine

Intravenous (IV) infusion

DRUG

Fludarabine

IV infusion

Trial Locations (20)

1090

RECRUITING

Sankt Anna-Kinderspital, Vienna

10065

RECRUITING

Memorial Sloan Kettering Cancer Center - New York, New York

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20900

RECRUITING

Fondazione IRCCS San Gerardo dei Tintori (Ospedale San Gerardo), Monza

28009

RECRUITING

Hospital Infantil Universitario Niño Jesús, Madrid

30329

RECRUITING

Children's Healthcare of Atlanta, Atlanta

44093

RECRUITING

CHU de Nantes - Hôpital Femme-Enfant-Adolescent, Nantes

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

75019

RECRUITING

CHU de Reims - Hôpital Robert Debré, Paris

77030

RECRUITING

Texas Children's Hospital, Houston

80045

RECRUITING

Children's Hospital Colorado, Aurora

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

98105

RECRUITING

Seattle Children's Hospital, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

45229-3026

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

38105-3678

RECRUITING

St. Jude Children's Research Hospital, Memphis

M5G 1X8

RECRUITING

SickKids - The Hospital for Sick Children, Toronto

00165

RECRUITING

Ospedale Pediatrico Bambino Gesù, Roma

3584 CS

RECRUITING

Prinses Maxima Centrum Kinderoncologie, Utrecht

08035

RECRUITING

Hospital Universitari Vall d'Hebrón, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Kura Oncology

UNKNOWN

lead

PedAL BCU, LLC

OTHER

NCT06376162 - Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter